2256 fundamentals

Abbisko Cayman Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of drugs and small molecule oncology therapies. The firm designed and developed a pipeline of fourteen candidates focused on oncology, including six candidates at clinical stage. Its product candidates are primarily small molecules that focus on small molecule precision oncology and small molecule immuno-oncology therapeutic areas. The company was founded by Yao Chang Xu, Hong Ping Yu, and Zhui Chen on April 12, 2016 and is headquartered in Shanghai, China.